This invention is related to the area of disease diagnosis and prognosis. In particular, it relates to testing for disease markers in lumenectomy samples, such as samples from a blood vessel.
Cardiovascular disease frequently arises from the accumulation of atheromatous material on the inner walls of vascular lumens, particularly arterial lumens of the coronary and other vasculature, resulting in a condition known as atherosclerosis. Atherosclerosis occurs naturally as a result of aging, but may also be aggravated by factors such as diet, hypertension, heredity, vascular injury, and the like. Atheromatous and other vascular deposits restrict blood flow and can cause ischemia which, in acute cases, can result in myocardial infarction. Atheromatous deposits can have widely varying properties, with some deposits being relatively soft and others being fibrous and/or calcified. In the latter case, the deposits are frequently referred to as plaque.
One conventional treatment for cardiovascular disease is the use of stents. Endoluminal stents are commonly used to treat obstructed or weakened body lumens, such as blood vessels and other vascular lumens. Once deployed in the blood vessel, the stent can remain in the body lumen where it will maintain the patency of the lumen and/or support the walls of the lumen which surround it. One factor impeding the success of stent technology in endoluminal treatments is the frequent occurrence of in-stent restenosis, characterized by proliferation and migration of smooth muscle cells within and/or adjacent to the implanted stent, causing reclosure or blockage of the body lumen.
Atherosclerosis and restenosis can be treated in a variety of ways, including drugs, bypass surgery, and a variety of catheter-based approaches which rely on intravascular debulking or removal of the atheromatous or other material occluding a blood vessel. Of particular interest to the present invention, a variety of methods for cutting or dislodging material and removing such material from the blood vessel have been proposed, generally being referred to as atherectomy procedures. Atherectomy catheters intended to excise material from the blood vessel lumen generally employ a rotatable and/or axially translatable cutting blade which can be advanced into or past the occlusive material in order to cut and separate such material from the blood vessel lumen. In particular, side-cutting atherectomy catheters generally employ a housing having an aperture on one side, a blade which is rotated or translated by the aperture, and a balloon to urge the aperture against the material to be removed.
Although atherectomy catheters have proven very successful in treating many types of atherosclerosis and in-stent restenosis, improved atherectomy catheters and methods are continuously being pursued. For example, many currently available side-cutting atherectomy catheters have difficulty in capturing occluding material in the cutting aperture. To facilitate material capture, the cutting aperture is frequently elongated to increase the area into which the material can penetrate. Such elongation typically requires an equivalent lengthening of the cutter housing. Since most cutter housings are rigid, such lengthening makes it more difficult to introduce the distal end of the catheter through tortuous regions of the vasculature.
Another shortcoming of many currently available atherectomy catheters is that they typically require a balloon positioned opposite the cutting window to urge the cutting window into contact with occluding material. Such balloons, however, unduly increase the size of the distal portion of the catheter. Even with the balloon, the amount of material that can be removed by conventional atherectomy catheters is limited by the size of the cutting window. Other disadvantages of some catheters include cutting elements with less than ideal hardness, inadequate storage space within the catheter for containing removed material, sub-optimal guide wire lumens, and/or the like. In addition, the available atherectomy catheters generally provide material insufficient in quantity and/or quality for testing by many histological, array, proteomic or other biochemical or molecular methods. For example, in one report a device and method available to the artisan collected less than about 50 mg of tissue. (Safian et al., Circulation 82: 305-307 (1990)). This amount of material is not typically enough to carry out more than one test, or is insufficient to successfully carry out a number of diagnostic tests available to the physician or researcher.
Recently atherectomy catheters have been developed which can access small, tortuous regions of the vasculature and remove atheromatous and other occluding materials from within blood vessels and stents in a controlled fashion. In particular, these atherectomy catheters facilitate capturing and invagination of atheromatous materials. Particularly, these catheters are capable of in vivo capturing and removing of continuous tissue strands of sufficient quantity and quality for testing in vitro. These catheters and methods for their use are adaptable for use in a variety of body lumens, including but not limited to coronary and other arteries.
There is a continuing need in the art to develop new methods for accurate and early assessments of disease states and incipient or imminent disease states.
One aspect of the invention provides a method of determining the presence or likelihood of a condition of a patient. A lumenectomy material comprising at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of a subject is tested for the presence of at least one marker of a disease selected from the group consisting of hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, and diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the subject.
This and other embodiments which will be apparent to those of skill in the art upon reading the specification provide the art with methods for detection, diagnosis, and prognosis of diseases.
The inventors have developed methods for testing for the presence or likelihood of certain diseases. Rather than testing for certain disease makers in serum, for example, the present methods test for disease markers in lumenectomy samples, such as artherectomy samples.
Diseases which can be evaluated using the method of the invention include, but are not limited to, hypertension, hyperlipidemia, depression, obesity, diabetes, insulin resistance, metabolic syndrome, kidney disease, and kidney damage. Lumens from which the test sample can be harvested include blood vessels, such as the coronary artery, the gastrointestinal tract, such as the intestine, airways, such as the bronchi and the trachea, tear ducts, mammary ducts, kidney tubules, ureters, bladders, urethras, vas deferens, epididymis, and fallopian tubes.
Lumenectomy catheters which can be used to collect the samples of the present invention are described in U.S. application publication No. 20050177068, the disclosure of which is expressly incorporated herein. Other lumenectomy catheters which provide sufficient material for testing may also be used. In certain embodiments the amount of material collected can be about 1 mg to about 2000 mg, more typically the amount of material can be about 1 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, about 300 mg to about 400 mg, about 400 mg to about 500 mg, about 500 mg to about 600 mg, about 600 mg to about 700 mg, about 700 mg to about 800 mg, or about 800 mg up to about 2000 mg.
The material excised from the body lumen will vary in length and will depend on the catheter configuration, the type of material removed, the body lumen, and the like. However, in certain embodiments, the material will be in the form of continuous strands that have a substantially consistent depth and width of tissue cuts. The material is typically longer than the length of the cutting window (but it may be shorter), and typically has a length of at least about 2.0 mm, although the length may be between about 0.5 cm up to about 10 cm or longer in length. Advantageously, the planing action of the catheter provides a material tissue structure that reflects the actual in vivo tissue structure, and provides information about larger portions of the disease state of the body lumen.
Markers which can be tested are any for which an association has been established between the marker and the disease or imminent onset of the disease. Markers can be, for example, proteins, enzymes, or RNAs. The marker can be the presence or absence of a substance or an increased or decreased level of the substance. The material collected from the body lumen is typically a continuous strip of tissue that may be longer than the cutting window of the lumenectomy catheter. This material can provide a sufficient amount of sample material of a quality and quantity that can be used for one or more of genomic screening, DNA hybridization, RNA hybridization, gene expression analysis, PCR amplification, proteomic testing, drug efficacy screening, protein marker detection, DNA marker detection, RNA marker detection, histological testing, histopathology, cytopathology, cell and tissue type analysis, biopsy, or the like. In addition, the material collected may be sufficient in amount and quality for testing for one or more of the presence of a DNA, an RNA, or a protein marker.
Generally the markers may be in the category of apoptotic markers, cell cycle proteins, transcriptional factors, proliferative markers, endothelial growth factors, adhesion molecules, cytokines, chemokines, chemokine receptors, inflammation markers, coagulation factors, fibrinolytic factors, oxidative stress related molecules, extracellular matrix molecules, interleukins, growth factors, glycoproteins, proteoglycans, cell-surface markers, serum markers, or immune factors. Other types of markers which are established as associated with the diseases may be used as well.
Specific markers which may be used include C-reactive protein, interleukin-6, and/or intracellular adhesion molecule-1 for depression; angiotensin II, aldosterone, and/or atrial natriuretic factor for hypertension; tissue factor pathway inhibitor, plasminogen activator inhibitor-1, triglycerides, and/or apolipoprotein B for hyperlipidemia; triglycerides for insulin resistance; low density lipoprotein, Remnant-like particles-cholesterol and/or triglycerides for diabetes; triglyceride-rich lipoproteins for kidney damage. Other markers as are known in the art and which are associated with specific diseases can be used as well, without limitation.
Particular types of tests that can be carried out successfully on the excised lumenectomy material removed by the methods of the present invention include, but are not limited to, enzyme histochemistry, immunohistology, immunocytochemistry, immunoassays, immunofluorescent assays, immunoprecipitation assays, ELISA, flow cytometry, fluorescent activated cell sorting, radioimmunochemistry, electrophoresis, two-dimensional gel electrophoresis, Western blotting, protein sequencing, mass spectrometry, proteomic analysis, and protein microarray analysis. Further, Nothern blotting, RNase protection assays, in situ hybridization assays, DNA microarray testing, reverse transcription polymerase chain reaction PCR (RT-PCR), Southern blotting, DNA sequencing, PCR amplification, single strand conformational polymorphism assays, single strand polymorphism (SNP) assays, and serial analysis of gene expression (SAGE) assays can be successfully carried out with the lumenectomy material compositions collected by the disclosed methods.
Prior to testing the harvested material, the material can optionally be placed in a preserving agent, a tissue fixative, or a preparation agent compatible with a particular test to be run. Agents known in the art for preserving, fixing or preparing the material for later use include, for example, saline, heparinized saline, liquid nitrogen, formalin, a membrane lysis agent, an RNA or DNA preparation agent, and the like. The material can be collected in a single access or can be collected in multiple translumenal accesses in the same patient. Further the material is typically at least one substantially consistent, continuous strip of material that maintains the structure of the material as it was removed from the inner surface of the lumen of the patient. Also, sample material can be collected from one, two, or more sites in the same or a different body lumen of a patient.
The lumenectomy catheters can achieve selective plaque excision, i.e., they can specifically target diseased areas. Thus the samples are enriched in disease markers, relative to serum samples, in which disease markers are diluted with other substances from non-diseased tissues. Nonetheless, serum testing may be performed in conjunction with the lumenectomy evaluation, and the results used, for example, to confirm each other.
The above disclosure generally describes the present invention. All references disclosed herein are expressly incorporated by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.
The disclosure of each reference cited is expressly incorporated herein.
Number | Name | Date | Kind |
---|---|---|---|
2178700 | Henry | Nov 1939 | A |
3705577 | Sierra | Dec 1972 | A |
3815604 | O'Malley et al. | Jun 1974 | A |
3837345 | Matar | Sep 1974 | A |
3995619 | Glatzer | Dec 1976 | A |
4210146 | Banko | Jul 1980 | A |
4669469 | Gifford et al. | Jun 1987 | A |
4696298 | Higgins et al. | Sep 1987 | A |
4771774 | Simpson et al. | Sep 1988 | A |
4781186 | Simpson et al. | Nov 1988 | A |
4817613 | Jaraczewski et al. | Apr 1989 | A |
4819635 | Shapiro | Apr 1989 | A |
4850957 | Summers | Jul 1989 | A |
4926858 | Gifford, III et al. | May 1990 | A |
RE33258 | Onik et al. | Jul 1990 | E |
4966604 | Reiss | Oct 1990 | A |
4979951 | Simpson | Dec 1990 | A |
4986807 | Farr | Jan 1991 | A |
4994067 | Summers | Feb 1991 | A |
5024651 | Shiber | Jun 1991 | A |
5047040 | Simpson et al. | Sep 1991 | A |
5053044 | Mueller et al. | Oct 1991 | A |
5071425 | Gifford et al. | Dec 1991 | A |
5084010 | Plaia et al. | Jan 1992 | A |
5087265 | Summers | Feb 1992 | A |
5092873 | Simpson et al. | Mar 1992 | A |
5154724 | Andrews | Oct 1992 | A |
5181920 | Mueller et al. | Jan 1993 | A |
5217474 | Zacca et al. | Jun 1993 | A |
5222966 | Perkins et al. | Jun 1993 | A |
5224488 | Neuffer | Jul 1993 | A |
5224949 | Gomringer et al. | Jul 1993 | A |
5226909 | Evans et al. | Jul 1993 | A |
5226910 | Kajiyama et al. | Jul 1993 | A |
5242460 | Klein et al. | Sep 1993 | A |
5250059 | Andreas et al. | Oct 1993 | A |
5250065 | Clement et al. | Oct 1993 | A |
5269793 | Simpson et al. | Dec 1993 | A |
5282484 | Reger | Feb 1994 | A |
5285795 | Ryan et al. | Feb 1994 | A |
5312425 | Evans et al. | May 1994 | A |
5318032 | Lonsbury et al. | Jun 1994 | A |
5318528 | Heaven et al. | Jun 1994 | A |
5321501 | Swanson et al. | Jun 1994 | A |
5372602 | Burke | Dec 1994 | A |
5395313 | Naves et al. | Mar 1995 | A |
5403334 | Evans et al. | Apr 1995 | A |
5419774 | Willard et al. | May 1995 | A |
5429136 | Milo et al. | Jul 1995 | A |
5431673 | Summers et al. | Jul 1995 | A |
5441510 | Simpson et al. | Aug 1995 | A |
5459570 | Swanson et al. | Oct 1995 | A |
5470415 | Perkins et al. | Nov 1995 | A |
5485042 | Burke | Jan 1996 | A |
5491524 | Hellmuth et al. | Feb 1996 | A |
5505210 | Clement | Apr 1996 | A |
5507292 | Jang et al. | Apr 1996 | A |
5507760 | Wynne et al. | Apr 1996 | A |
5507795 | Chiang et al. | Apr 1996 | A |
5514115 | Frantzen et al. | May 1996 | A |
5527325 | Conley et al. | Jun 1996 | A |
5549601 | McIntyre et al. | Aug 1996 | A |
5569277 | Evans et al. | Oct 1996 | A |
5571122 | Kelly et al. | Nov 1996 | A |
5571130 | Simpson et al. | Nov 1996 | A |
5584842 | Fogarty et al. | Dec 1996 | A |
5620447 | Smith et al. | Apr 1997 | A |
5624457 | Farley et al. | Apr 1997 | A |
5632754 | Farley et al. | May 1997 | A |
5634464 | Jang et al. | Jun 1997 | A |
5643296 | Hundertmark et al. | Jul 1997 | A |
5643298 | Nordgren et al. | Jul 1997 | A |
5665098 | Kelly et al. | Sep 1997 | A |
5669920 | Conley et al. | Sep 1997 | A |
5674232 | Halliburton | Oct 1997 | A |
5695506 | Pike et al. | Dec 1997 | A |
5700687 | Finn | Dec 1997 | A |
5709698 | Adams et al. | Jan 1998 | A |
5731489 | Ganten et al. | Mar 1998 | A |
5733296 | Rogers et al. | Mar 1998 | A |
5741270 | Hansen et al. | Apr 1998 | A |
5776114 | Frantzen et al. | Jul 1998 | A |
5816923 | Milo et al. | Oct 1998 | A |
5836957 | Schulz et al. | Nov 1998 | A |
5843103 | Wulfman | Dec 1998 | A |
5868685 | Powell et al. | Feb 1999 | A |
5868767 | Farley et al. | Feb 1999 | A |
5911734 | Tsugita et al. | Jun 1999 | A |
5916210 | Winston | Jun 1999 | A |
5938671 | Katoh et al. | Aug 1999 | A |
5948184 | Frantzen et al. | Sep 1999 | A |
5951482 | Winston et al. | Sep 1999 | A |
5954745 | Gertler et al. | Sep 1999 | A |
5968064 | Selmon et al. | Oct 1999 | A |
5989281 | Barbut et al. | Nov 1999 | A |
6010449 | Selmon et al. | Jan 2000 | A |
6013072 | Winston et al. | Jan 2000 | A |
6022362 | Lee et al. | Feb 2000 | A |
6027450 | Brown et al. | Feb 2000 | A |
6027514 | Stine et al. | Feb 2000 | A |
6036656 | Slater | Mar 2000 | A |
6036707 | Spaulding | Mar 2000 | A |
6048349 | Winston et al. | Apr 2000 | A |
6063093 | Winston et al. | May 2000 | A |
6068638 | Makower | May 2000 | A |
6081738 | Hinohara et al. | Jun 2000 | A |
6106515 | Winston et al. | Aug 2000 | A |
6120515 | Rogers et al. | Sep 2000 | A |
6120516 | Selmon et al. | Sep 2000 | A |
6126649 | VanTassel et al. | Oct 2000 | A |
6134003 | Tearney et al. | Oct 2000 | A |
6157852 | Selmon et al. | Dec 2000 | A |
6159225 | Makower | Dec 2000 | A |
6183432 | Milo | Feb 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6191862 | Swanson et al. | Feb 2001 | B1 |
6193676 | Winston et al. | Feb 2001 | B1 |
6217527 | Selmon et al. | Apr 2001 | B1 |
6217549 | Selmon et al. | Apr 2001 | B1 |
6221049 | Selmon et al. | Apr 2001 | B1 |
6228076 | Winston et al. | May 2001 | B1 |
6231546 | Milo et al. | May 2001 | B1 |
6231549 | Noecker et al. | May 2001 | B1 |
6235000 | Milo et al. | May 2001 | B1 |
6241667 | Vetter et al. | Jun 2001 | B1 |
6241744 | Imran et al. | Jun 2001 | B1 |
6258052 | Milo | Jul 2001 | B1 |
6266550 | Selmon et al. | Jul 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6299622 | Snow et al. | Oct 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6330884 | Kim | Dec 2001 | B1 |
6355005 | Powell et al. | Mar 2002 | B1 |
6375615 | Flaherty et al. | Apr 2002 | B1 |
6394976 | Winston et al. | May 2002 | B1 |
6398798 | Selmon et al. | Jun 2002 | B2 |
6428552 | Sparks | Aug 2002 | B1 |
6443966 | Shiu | Sep 2002 | B1 |
6445939 | Swanson et al. | Sep 2002 | B1 |
6447525 | Follmer et al. | Sep 2002 | B2 |
6623496 | Snow et al. | Sep 2003 | B2 |
6638233 | Corvi et al. | Oct 2003 | B2 |
20020022788 | Corvi et al. | Feb 2002 | A1 |
20020077642 | Patel et al. | Jun 2002 | A1 |
20030018346 | Follmer et al. | Jan 2003 | A1 |
20030100486 | Ridker et al. | May 2003 | A1 |
20030120295 | Simpson et al. | Jun 2003 | A1 |
20030125757 | Patel et al. | Jul 2003 | A1 |
20030125758 | Simpson et al. | Jul 2003 | A1 |
20030219813 | Yang et al. | Nov 2003 | A1 |
20040167553 | Simpson | Aug 2004 | A1 |
20040167554 | Simpson | Aug 2004 | A1 |
20050154407 | Simpson | Jul 2005 | A1 |
20050177050 | Cohen | Aug 2005 | A1 |
20050177068 | Simpson | Aug 2005 | A1 |
20050222519 | Simpson | Oct 2005 | A1 |
20050222663 | Simpson et al. | Oct 2005 | A1 |
20060032508 | Simpson | Feb 2006 | A1 |
20060235366 | Simpson | Oct 2006 | A1 |
20060236019 | Soito et al. | Oct 2006 | A1 |
20060239982 | Simpson | Oct 2006 | A1 |
20070078469 | Soito et al. | Apr 2007 | A1 |
20070173901 | Reeve | Jul 2007 | A1 |
20070218519 | Urdea et al. | Sep 2007 | A1 |
20080065124 | Olson | Mar 2008 | A1 |
20080065125 | Olson | Mar 2008 | A1 |
Number | Date | Country |
---|---|---|
0 999 447 | May 2000 | EP |
WO 0018903 | Apr 2000 | WO |
WO 0219966 | Mar 2002 | WO |
WO 0245598 | Jun 2002 | WO |
WO 03016910 | Feb 2003 | WO |
WO 2004089184 | Oct 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20070196926 A1 | Aug 2007 | US |